EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Multi-cancer early detection tests for general population screening: a systematic literature review

Ros Wade iD, Sarah Nevitt iD, Yiwen Liu iD, Melissa Harden iD, Claire Khouja iD, Gary Raine iD, Rachel Churchill iD, Sofia Dias iD

Health Technology Assessment · 2025-01 · 1-105

DOI: 10.3310/dlmt1294 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2025-01. Verfasst von Ros Wade und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Reviews and Dissemination, University of York, York, UK. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasms, Mass Screening. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

General population cancer screening in the United Kingdom is limited to selected cancers. Blood-based multi-cancer early detection tests aim to detect potential cancer signals from multiple cancers in the blood. The use of a multi-cancer early detection test for population screening requires a high specificity and a reasonable sensitivity to detect early-stage disease so that the benefits of earlier diagnosis and treatment can be realised.

Objective

To undertake a systematic literature review of the clinical effectiveness evidence on blood-based multi-cancer early detection tests for screening.

Methods

Comprehensive searches of electronic databases (including MEDLINE and EMBASE) and trial registers were undertaken in September 2023 to identify published and unpublished studies of multi-cancer early detection tests. Test manufacturer websites and reference lists of included studies and pertinent reviews were checked for additional studies. The target population was individuals aged 50–79 years without clinical suspicion of cancer. Outcomes of interest included test accuracy, number and proportion of cancers detected (by site and stage), time to diagnostic resolution, mortality, potential harms, health-related quality of life, acceptability and satisfaction. The risk of bias was assessed using the quality assessment of diagnostic accuracy studies-2 checklist. Results were summarised using narrative synthesis. Stakeholders contributed to protocol development, report drafting and interpretation of review findings.

Results

Over 8000 records were identified. Thirty-six studies met the inclusion criteria: 1 ongoing randomised controlled trial, 13 completed cohort studies, 17 completed case-control studies and 5 ongoing cohort or case-control studies. Individual tests claimed to detect from 3 to over 50 different types of cancer. Diagnostic accuracy of currently available multi-cancer early detection tests varied substantially: Galleri ® (GRAIL, Menlo Park, CA, USA) sensitivity 20.8–66.3%, specificity 98.4–99.5% (three studies); CancerSEEK (Exact Sciences, Madison, WI, USA) sensitivity 27.1–62.3%, specificity 98.9– 99.1% (two studies); SPOT-MAS™ (Gene Solutions, Ho Chi Minh City, Vietnam) sensitivity 72.4–100%, specificity 97.0–99.9% (two studies); Trucheck™ (Datar Cancer Genetics, Bayreuth, Germany) sensitivity 90.0%, specificity 96.4% (one study); Cancer Differentiation Analysis (AnPac Bio, Shanghai, China) sensitivity 40.0%, specificity 97.6% (one study). AICS ® (AminoIndex Cancer Screening; Ajinomoto, Tokyo, Japan) screens for individual cancers separately, so no overall test performance statistics are available. Where reported, sensitivity was lower for detecting earlier-stage cancers (stages I–II) compared with later-stage cancers (stages III–IV). Studies of seven other multi-cancer early detection tests at an unclear stage of development were also summarised.

Limitations

Study selection was complex; it was often difficult to determine the stage of development of multi-cancer early detection tests. The evidence was limited; there were no completed randomised controlled trials and most included studies had a high overall risk of bias, primarily owing to limited follow-up of participants with negative test results. Only one study of Galleri recruited asymptomatic individuals aged over 50 in the United States of America; however, study results may not be representative of the United Kingdom's general screening population. No meaningful results were reported relating to patient-relevant outcomes, such as mortality, potential harms, health-related quality of life, acceptability or satisfaction.

Conclusions

All currently available multi-cancer early-detection tests reported high specificity (> 96%). Sensitivity was highly variable and influenced by study design, population, reference standard test used and length of follow-up. Future work Further research should report patient-relevant outcomes and consider patient and service impacts. Study registration This study is registered as PROSPERO CRD42023467901. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR161758) and is published in full in Health Technology Assessment ; Vol. 29, No. 2. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerNeoplasmsMass ScreeningHumansMiddle AgedAgedUnited KingdomSensitivity and SpecificityMaleFemaleTechnology Assessment, Biomedical

Stichwörter der Autor:innen

CANCER SCREENINGEARLY DETECTION OF CANCEREVIDENCE SYNTHESISMCEDMULTI-CANCER DETECTIONSYSTEMATIC LITERATURE REVIEW

Autor:innen und Institutionen

  • Centre for Reviews and Dissemination, University of York, York, UK.

ORCID-Profile: Ros Wade, Sarah Nevitt, Yiwen Liu, Melissa Harden, Claire Khouja, Gary Raine, Rachel Churchill, Sofia Dias

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Wade, R., Nevitt, S., Liu, Y., Harden, M., Khouja, C., Raine, G., Churchill, R., & Dias, S. (2025). Multi-cancer early detection tests for general population screening: a systematic literature review. Health Technology Assessment, 1-105. https://doi.org/10.3310/dlmt1294

Vancouver

Wade R, Nevitt S, Liu Y, Harden M, Khouja C, Raine G, et al. Multi-cancer early detection tests for general population screening: a systematic literature review. Health Technology Assessment. 2025:1-105. doi:10.3310/dlmt1294

BibTeX
@article{Wade2025,
  author = {Wade, Ros and Nevitt, Sarah and Liu, Yiwen and Harden, Melissa and Khouja, Claire and Raine, Gary and Churchill, Rachel and Dias, Sofia},
  title = {Multi-cancer early detection tests for general population screening: a systematic literature review},
  journal = {Health Technology Assessment},
  year = {2025},
  pages = {1--105},
  doi = {10.3310/dlmt1294}
}
Kostenlos starten →